Literature DB >> 21225465

Early occurrence of lung adenocarcinoma and breast cancer after radiotherapy of a chest wall sarcoma in a patient with a de novo germline mutation in TP53.

Alessandra Ferrarini1, Agnes Auteri-Kaczmarek, Alessia Pica, Nemya Boesch, Karl Heinimann, Stephan C Schäfer, Sara Vesnaver-Megalo, Viviane Cina, Jacques S Beckmann, Christian Monnerat.   

Abstract

We report a 26-year-old female patient who was diagnosed within 4 years with chest sarcoma, lung adenocarcinoma, and breast cancer. While her family history was unremarkable, DNA sequencing of TP53 revealed a germline de novo non-sense mutation in exon 6 p.Arg213X. One year later, she further developed a contralateral ductal carcinoma in situ, and 18 months later a jaw osteosarcoma. This case illustrates the therapeutic pitfalls in the care of a young cancer patient with TP53 de novo germline mutations and the complications related to her first-line therapy. Suggestion is made to use the less stringent Chompret criteria for germline TP53 mutation screening. Our observation underlines the possibly negative effect of radiotherapy in generating second tumors in patients with a TP53 mutation. We also present a review of six previously reported cases, comparing their cancer phenotypes with those generally produced by TP53 mutations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21225465     DOI: 10.1007/s10689-010-9415-9

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  27 in total

1.  Cancer. p53, guardian of the genome.

Authors:  D P Lane
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

2.  Multiple primary cancers in families with Li-Fraumeni syndrome.

Authors:  M Hisada; J E Garber; C Y Fung; J F Fraumeni; F P Li
Journal:  J Natl Cancer Inst       Date:  1998-04-15       Impact factor: 13.506

3.  Primitive neuroectodermal tumors of the cerebral hemispheres in two siblings with TP53 germline mutation.

Authors:  J Reifenberger; G Janssen; R G Weber; J Boström; V Engelbrecht; P Lichter; F Borchard; U Göbel; H G Lenard; G Reifenberger
Journal:  J Neuropathol Exp Neurol       Date:  1998-02       Impact factor: 3.685

Review 4.  A patient with 17 primary tumours and a germ line mutation in TP53: tumour induction by adjuvant therapy?

Authors:  C Nutting; R S Camplejohn; R Gilchrist; D Tait; P Blake; G Knee; W Q Yao; G Ross; C Fisher; R Eeles
Journal:  Clin Oncol (R Coll Radiol)       Date:  2000       Impact factor: 4.126

5.  Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene.

Authors:  Gaëlle Bougeard; Laurence Brugières; Agnès Chompret; Paul Gesta; Françoise Charbonnier; Alexander Valent; Cosette Martin; Grégory Raux; Jean Feunteun; Brigitte Bressac-de Paillerets; Thierry Frébourg
Journal:  Oncogene       Date:  2003-02-13       Impact factor: 9.867

6.  Delayed chromosome changes in gamma-irradiated normal and Li-Fraumeni fibroblasts.

Authors:  J M Boyle; A R Spreadborough; M J Greaves; J M Birch; J M Varley; D Scott
Journal:  Radiat Res       Date:  2002-02       Impact factor: 2.841

Review 7.  Li-Fraumeni syndrome--a molecular and clinical review.

Authors:  J M Varley; D G Evans; J M Birch
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations.

Authors:  Kelly D Gonzalez; Katie A Noltner; Carolyn H Buzin; Dongqing Gu; Cindy Y Wen-Fong; Vu Q Nguyen; Jennifer H Han; Katrina Lowstuter; Jeffrey Longmate; Steve S Sommer; Jeffrey N Weitzel
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

9.  Predominantly tumor-limited expression of a mutant allele in a Japanese family carrying a germline p53 mutation.

Authors:  Y Horio; H Suzuki; R Ueda; T Koshikawa; T Sugiura; Y Ariyoshi; K Shimokata; T Takahashi; T Takahashi
Journal:  Oncogene       Date:  1994-04       Impact factor: 9.867

10.  Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.

Authors:  Magali Olivier; David E Goldgar; Nayanta Sodha; Hiroko Ohgaki; Paul Kleihues; Pierre Hainaut; Rosalind A Eeles
Journal:  Cancer Res       Date:  2003-10-15       Impact factor: 12.701

View more
  5 in total

1.  The TP53 p.R337H mutation is uncommon in a Brazilian cohort of pediatric patients diagnosed with ependymoma.

Authors:  Taciani de Almeida Magalhães; Kleiton Silva Borges; Graziella Ribeiro de Sousa; Silvia Regina Brandalise; Ana Luiza Seidinger; Carlos Alberto Scrideli; Sueli Mieko Oba-Shinjo; José Andrés Yunes; Luiz Gonzaga Tone
Journal:  Neurol Sci       Date:  2019-11-14       Impact factor: 3.307

2.  Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes.

Authors:  Laurent Castéra; Sophie Krieger; Antoine Rousselin; Angélina Legros; Jean-Jacques Baumann; Olivia Bruet; Baptiste Brault; Robin Fouillet; Nicolas Goardon; Olivier Letac; Stéphanie Baert-Desurmont; Julie Tinat; Odile Bera; Catherine Dugast; Pascaline Berthet; Florence Polycarpe; Valérie Layet; Agnes Hardouin; Thierry Frébourg; Dominique Vaur
Journal:  Eur J Hum Genet       Date:  2014-02-19       Impact factor: 4.246

Review 3.  Li-Fraumeni syndrome: cancer risk assessment and clinical management.

Authors:  Kate A McBride; Mandy L Ballinger; Emma Killick; Judy Kirk; Martin H N Tattersall; Rosalind A Eeles; David M Thomas; Gillian Mitchell
Journal:  Nat Rev Clin Oncol       Date:  2014-03-18       Impact factor: 66.675

Review 4.  Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.

Authors:  Felipe Batalini; Ellie G Peacock; Lindsey Stobie; Alison Robertson; Judy Garber; Jeffrey N Weitzel; Nadine M Tung
Journal:  Breast Cancer Res       Date:  2019-09-18       Impact factor: 6.466

5.  Molecular profile of tongue cancer in an 18-year-old female patient with no recognizable risk factor.

Authors:  Melvin A Ambele; Michael S Pepper; Marlene B van Heerden; Willie F P van Heerden
Journal:  Laryngoscope Investig Otolaryngol       Date:  2019-04-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.